scholarly article | Q13442814 |
P50 | author | Taylor A Doherty | Q38325230 |
Bruce L Zuraw | Q56663848 | ||
P2093 | author name string | David H Broide | |
Andrew A White | |||
Sandra C Christiansen | |||
Maya R Karta | |||
Alex S Kim | |||
Jacqueline J Eastman | |||
Kellen J Cavagnero | |||
Adam S Deconde | |||
P2860 | cites work | Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2 | Q28166254 |
A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge | Q28195706 | ||
Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease | Q30276354 | ||
Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma | Q33921113 | ||
Enhanced innate type 2 immune response in peripheral blood from patients with asthma | Q34111924 | ||
Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness | Q34624361 | ||
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease | Q34892917 | ||
At the bench: understanding group 2 innate lymphoid cells in disease. | Q35115465 | ||
Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. | Q35634065 | ||
IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs | Q35685426 | ||
Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis | Q36037301 | ||
Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway | Q36119388 | ||
Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. | Q36157993 | ||
TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation | Q36798825 | ||
Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production | Q36991150 | ||
Chronic Rhinosinusitis with Nasal Polyps | Q37080775 | ||
Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis | Q37138334 | ||
Th9 and allergic disease | Q37552040 | ||
Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. | Q37619448 | ||
Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells | Q37691114 | ||
Innate and adaptive immune responses in asthma | Q38007827 | ||
Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites | Q38013046 | ||
Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease | Q41146048 | ||
Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease | Q42950579 | ||
Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge | Q43069043 | ||
Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma | Q43796672 | ||
Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics | Q44675978 | ||
Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations | Q44856833 | ||
Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. | Q44891908 | ||
Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations | Q48379723 | ||
Omalizumab in the treatment of aspirin-exacerbated respiratory disease. | Q51661831 | ||
IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. | Q53793238 | ||
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction | Q69304770 | ||
Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma | Q72964940 | ||
Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells | Q80736011 | ||
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 | Q84933191 | ||
Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy | Q85294417 | ||
Type 2 innate lymphoid cells in induced sputum from children with severe asthma | Q85908714 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | aspirin | Q18216 |
P304 | page(s) | 101-108.e3 | |
P577 | publication date | 2017-03-06 | |
P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
P1476 | title | Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease | |
P478 | volume | 140 |
Q38739370 | Advanced Role of Neutrophils in Common Respiratory Diseases |
Q93352014 | Airway innate lymphoid cells in the induction and regulation of allergy |
Q64083734 | Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management |
Q89098605 | Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease |
Q48204581 | Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. |
Q47719552 | Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. |
Q95840967 | ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure |
Q92100352 | Increased expression of type 2 innate lymphoid cells in pediatric patients with allergic rhinitis |
Q64255314 | Innate Lymphoid Cells in Mucosal Immunity |
Q49980468 | Innate lymphoid cells and allergic disease |
Q38699307 | Leukotriene C4 Potentiates IL-33-Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation |
Q55192190 | Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines. |
Q99575721 | Lipid-mediated innate lymphoid cell recruitment and activation in AERD |
Q90330860 | NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets |
Q90108933 | Omalizumab for Aspirin-Hypersensitivity and Leukotriene Overproduction in Aspirin-Exacerbated Respiratory Disease: A Randomized Trial |
Q90271537 | Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells |
Q58086903 | Prostaglandin-cytokine crosstalk in chronic inflammation |
Q97521492 | Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation |
Q90884836 | Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps |
Q47656375 | Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis |
Q90393410 | The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy |
Q48093883 | The role of basophils as innate immune regulatory cells in allergy and immunotherapy |
Search more.